MenopauseResearch Wiki

A living synthesis mined nightly by VaultMiner. Domain: Menopause, HRT, women's healthy-aging research

Last updated: 2026-08-11

Cognitive and Brain Health

• Brain fog during menopause is linked to hormonal changes affecting the brain, not just stress or dementia, according to research from the SWAN Study and Dr. Lisa Mosconi's work. (source: 2026-05-24-GAoogzA-Wm4.md)
• Most brain supplements lack testing on women, despite claims to support brain health and memory in perimenopause and menopause. (source: 2026-05-26-FG6Zu2N_ltk.md)
• Only 3% of studies in neuroscience examine a female-only population, leaving significant gaps in understanding how estrogen and hormonal changes impact women's brain health. (source: 2026-04-28-s6GrCAl5tUI.md)
• Regular physical activity is associated with a reduced risk of dementia in both pre- and postmenopausal women, with even light activity like walking showing benefits in postmenopausal women with higher BMI. (source: lim-2026-role-of-physical-activity-in-protecting-against-dementia.md)
• Intrinsic neural connectivity within an emotion regulation network shows stage-specific patterns across the menopausal transition, with perimenopause characterized by distinct frontal interaction patterns. (source: weinmar-2026-distinct-intrinsic-neural-connectivity-of-an-emotion-regulation.md)
• Women account for nearly two-thirds of individuals with Alzheimer's disease and demonstrate important biological and clinical differences compared with men. APOE ε4 confers greater risk in women, while menopause, depression, chronic stress, adverse pregnancy outcomes, and metabolic dysfunction may further increase vulnerability. (source: just-2026-considerations-in-alzheimer-s-disease-in-women.md)
• Menopause marks an inflection point for vascular injury, neurodegeneration, and disability accumulation in neurological conditions like stroke, migraine, epilepsy, multiple sclerosis, Parkinson's disease, and Alzheimer's disease. Perimenopausal hormonal fluctuations (especially estrogen) may exacerbate migraines and seizures in susceptible women. HRT has heterogenous effects, with cognitive benefit in premature ovarian insufficiency but increased stroke risk in older women. (source: roeder-2026-the-neurology-of-menopause.md)
• Neural correlates of menopausal symptoms, measured by the Kupperman Index (KMI), demonstrate significant valence-specific patterns during an emotional Free Association Semantic Task (FAST) using functional near-infrared spectroscopy (fNIRS). Symptom severity correlates with activation in the right dorsolateral prefrontal cortex (DLPFC) and inferior frontal gyrus (IFG) during negative valence tasks, and with the left frontal eye fields (FEF) during positive valence tasks, suggesting potential neuromarkers for menopause. (source: chen-2026-neural-correlates-of-menopausal-symptoms-revealed-by-emotion-related.md)
• A randomized controlled trial found that aerobic exercise significantly improves executive functions in post-menopausal women compared to stretching/toning, with benefits emerging at 3 months and sustained at 6 months. This suggests aerobic exercise as a relevant strategy to promote brain health in women at higher risk for Alzheimer's disease. (source: sanz-2026-can-menopausal-status-moderate-the-effects-of-aerobic.md)
• Higher baseline serum GlycA (a systemic inflammatory marker) was associated with worse future working memory, while higher baseline complement factor 4 and increases in complement factor 3 and 4 over time appeared cognitively protective in midlife women from the SWAN Study. (source: qi-2026-inflammatory-and-immune-biomarkers-over-midlife-and-future.md)
• Age-associated estrogen decline is a systemic driver of neurodegeneration. In a mouse model of surgical menopause, estrogen deficiency exacerbated retinal ganglion cell (RGC) loss by about 60% and severely impaired functional recovery after ischemia-reperfusion injury. Combined treatment with the selective estrogen receptor modulator Raloxifene and the Fas receptor antagonist KP7-6 produced a powerful synergistic effect, limiting RGC somatic loss to 18% and restoring retinal function to near-physiological levels. This identifies endocrine aging as a modifiable driver of neuronal vulnerability and suggests a combinatorial therapeutic strategy for age-related neurodegenerative disorders. (source: rodak-2026-crosstalk-between-estrogen-signaling-and-fas-mediated-apoptosis-deter.md)
• HRT use within 5 years before or after menopause (OR 0.70, 95% CI 0.50-0.98) or for 8 to 16 years (OR 0.44, 95% CI 0.24-0.79) was associated with lower odds of limbic-predominant age-related TDP-43 encephalopathy neuropathological change (LATE-NC), a cause of dementia resembling Alzheimer's disease, in older adults. This highlights the importance of HRT timing and duration for its potential neuroprotective effects. (source: kim-2026-hormone-replacement-therapy-and-its-association-with-late-nc.md)

Mental Health and Menopause

• Mind-body exercise (e.g., yoga, tai chi) is associated with lower depressive symptoms in Chinese perimenopausal women, and this association is linked to higher social support and subjective well-being. Urban residents reported lower levels of mind-body exercise, social support, and well-being and higher depressive symptoms compared with rural residents. (source: zhu-2026-the-association-between-mind-body-exercise-and-depressive-symptoms.md)
• Perceived stress is a central mediator linking negative life events to psychosocial quality of life during the menopausal transition, with resilience, self-efficacy, and social support acting as indirect protective factors through stress reduction. (source: kuck-2026-perceived-stress-as-a-mediator-between-negative-life.md)
• Shikimic acid (SA), a natural compound, exerts antidepressant-like effects via rapamycin-sensitive mTORC1-dependent mechanisms within the medial prefrontal cortex (mPFC) in mice. SA reversed ovariectomy-induced increases in immobility in the forced swim test, and this effect was completely prevented by intra-mPFC rapamycin, supporting SA as a candidate compound for novel rapid-acting antidepressants relevant to menopause-associated depression. (source: deyama-2026-rapamycin-sensitive-mtorc1-signaling-in-the-medial-prefrontal-cortex.md)

Hormone Replacement Therapy (HRT)

• The FDA removed the HRT 'Black Box' warning in 2025, a shift not widely discussed, and approved dual neurokinin receptor antagonists like elinzanetant, which reduce vasomotor symptoms by 74% without hormones. (source: 2026-05-26.md)
• The original Women's Health Initiative study on HRT safety is contested by modern specialists who argue it inappropriately tested older women on synthetic hormones. (source: 2026-05-26.md)
• There is debate over the safety of compounded hormone medications, with some doctors warning against them and others seeing them as necessary for specific formulations. HRT is central to this debate. (source: 2026-05-26.md)
• Doctors debate the appropriate limits for testosterone replacement therapy in women, with some maintaining levels above standard guidelines if the patient feels well. (source: 2026-05-26.md)
• The Women's Health Initiative study led to a 68% drop in HRT prescriptions by 2008, but the FDA reversed its warning in 2025 after recognizing flaws in the original study. (source: 2026-04-28-Ap0KrPbyVoU.md)
• Estrogen-only HRT was not associated with increased headache severity in postmenopausal women, while estrogen-progestin therapy was linked to worsening headaches, especially in those with a history of migraine. (source: crowe-2026-menopausal-hormone-therapy-migraine-history-and-headache-severity.md)
• Transdermal estradiol gel achieves serum levels (~60 pg/mL) associated with optimal cardiovascular and skeletal benefits while effectively reducing vasomotor symptoms. (source: piette-2026-optimizing-estradiol-serum-levels-for-optimal-skeletal-and.md)
• No flares were reported with HRT in women with acute hepatic porphyria, though flares occurred with combined oral contraceptives (46.6%) and progesterone-containing intrauterine devices (28.5%). Levonorgestrel-based therapies were better tolerated. (source: arandjelovic-2026-tolerability-of-hormonal-treatments-in-acute-hepatic-porphyria.md)
• HRT should be individualized according to comorbidities, formulation, and route, with preference for transdermal or low-dose regimens in high-risk populations. (source: sachdeva-2026-systematic-review-hormone-replacement-therapy-in-postmenopausal-wo.md)
• Hormone replacement (HRT) before brain death increases organ donation rates after catastrophic brain injury, with combinations like methylprednisolone and levothyroxine showing the greatest benefit. (source: nordham-2026-hormone-replacement-before-brain-death-increases-organ-donation.md)
• Initiating HRT within the first year after chemoradiation for locally advanced cervical cancer reduces metabolic, skeletal, and cerebrovascular morbidity and improves overall survival. (source: lu-2026-association-of-hormone-therapy-with-long-term-outcomes-after.md)
• Women with a history of pre-eclampsia have a reduced risk of breast cancer, and HRT use increases breast cancer risk similarly in women with or without a history of pre-eclampsia. (source: joensuu-2026-reduced-breast-cancer-risk-in-women-with-a.md)
• Combined menopausal HRT (estrogen-progestin) was associated with an increased risk of Parkinson's disease (RR 1.40; 95% CI 1.07-1.82), while estrogen-only therapy showed no significant association (RR 1.01; 95% CI 0.81-1.27). (source: macedo-2026-differential-effects-of-hormone-therapy-formulations-on-parkinson-s.md) , [DUPLICATE REMOVED, KEPT IN NEUROLOGICAL CONDITIONS]
• Systemic HRT may be suitable for carefully chosen survivors of non-hormone-dependent gynecologic cancers (e.g., most vulvar, vaginal, cervical, and epithelial ovarian cancers), while patients with hormonally sensitive tumors should generally avoid systemic HRT. (source: da-2026-menopausal-hormone-therapy-and-comprehensive-postmenopausal-care-in.md)
• Nulliparity and later age at menopause were associated with higher ER-positivity in breast cancer (p-trend=0.021 and 0.001, respectively), with corresponding OR[ER+] (95% CI) = 1.49 (1.16-1.90) for nulliparous vs. parous. (source: adams-2026-clarifying-risk-factor-associations-with-quantitative-breast-tumor-fe.md)
• Current combined HRT (MHT) use was associated with lower grade breast cancer (p-trend<0.001), with OR [grade1] = 3.37 (2.69-4.21) for current vs. never users. (source: adams-2026-clarifying-risk-factor-associations-with-quantitative-breast-tumor-fe.md)
• Manufacturer-combined estrogen and progestogen therapy was associated with significantly lower risk of endometrial cancer (HR 0.592, 95% CI: 0.437-0.801), while tibolone use showed increased risk when used for more than four years (HR 1.518, 95% CI: 1.152-1.999). (source: yoon-2026-association-between-type-and-duration-of-menopausal-hormone.md)
• Higher baseline levels of LDL cholesterol when using CEE+MPA or lower levels of HDL cholesterol when using CEE resulted in an increased risk for CHD across all age groups. Prior treatment of hyperlipidemia demonstrated no increased risk of CHD in patients treated with CEE+MPA or CEE compared with those receiving placebo. (source: rossouw-2026-influence-of-cardiometabolic-status-on-cardiovascular-effects-of.md)
• Of 318,621 eligible women, 21.7% initiated systemic HRT within 1 year. Predictors of HT initiation included younger age (adjusted odds ratio [aOR] 2.17; 95% CI, 2.12-2.23), prior hysterectomy (aOR 1.98; 95% CI, 1.77-2.21), and local hormone use (aOR 3.25; 95% CI, 3.05-3.47). Initiation was significantly lower among women with obesity (aOR 0.78; 95% CI, 0.75-0.81), diabetes (aOR 0.69; 95% CI, 0.66-0.72), and Black racial identification (aOR 0.78; 95% CI, 0.68-0.89). (source: sriprasert-2026-initiation-and-duration-of-systemic-hormone-therapy-for.md)
• HRT was found to be independently associated with reduced medical complications following primary total shoulder arthroplasty (TSA), including lower incidence of acute kidney injury (AKI), urinary tract infection (UTI), pneumonia, and transfusion. (source: ninness-2026-hormone-replacement-therapy-and-complications-after-primary-total.md)
• Reanalysis of the Women's Health Initiative and recent studies have demonstrated the protective role of estrogen in cardiovascular disease (CVD) and bone health, particularly when initiated before the age of 60. There is an increased risk of venous thromboembolism (VTE) with oral formulations, but formulations using transdermal estradiol and micronized Progesterone do not appear to increase VTE risk. HRT may be helpful in perimenopausal and menopausal mood disorders. The timing hypothesis may be applicable to both CVD and cognition. (source: switzer-2026-management-of-menopausal-hormone-therapy.md)
• For otherwise healthy women less than 60 years old or within 10 years of menopause, HRT is a safe and effective treatment for vasomotor symptoms. Although the role of MHT is being studied for various preventive strategies, major medical societies do not yet recommend MHT for primary prevention. (source: switzer-2026-management-of-menopausal-hormone-therapy.md)
• Follow-up consultations for women on HRT should address symptom control, side effects, and bleeding patterns. The variety of formulations allows individualization, and initial difficulties are common but most women can stabilize therapy within a few months. (source: spencer-2026-troubleshooting-menopause-hormone-therapy.md)

Exercise and Physical Health

• Aerobic exercise alone does not reliably reduce hot flash frequency, and high-intensity interval training (HIIT) can worsen symptoms for women with elevated cortisol and poor sleep. (source: 2026-05-26.md)
• Researchers disagree on the safety of HIIT for menopausal women, with some advocating for its benefits and others warning it can overwhelm a depleted system. (source: 2026-05-26.md)
• Postmenopausal women cannot out-exercise visceral fat with cardio alone; resistance training and dietary changes are more effective, particularly given the role of obesity in metabolic risk. (source: 2026-05-25-tqktQoWSaWE.md)
• Women in perimenopause and menopause have different strength and cardiovascular needs than younger women, requiring tailored exercise routines. (source: 2026-05-12-7-c9tHCf7X0.md)
• Oestrogen deficiency (ovariectomized model) impairs serial sarcomerogenesis and functional recovery following immobilization in female skeletal muscle, suggesting estradiol's role in muscle repair. (source: kirkup-2026-alterations-to-longitudinal-muscle-morphology-and-mechanical-functio.md)
• Resistance training mitigates estrogen deficiency-induced bone deterioration more effectively than aerobic training, increasing osteocyte density, RUNX2 expression, and muscle fiber cross-sectional area in ovariectomized mice. (source: machado-2026-comparing-aerobic-and-resistance-training-in-estrogen-deficiency.md)
• Aging in females is associated with lower estrogen receptor α (ERα) and GPER1 protein expression in skeletal muscle, and lower ER expression is associated with lower eNOS expression, indicating links to nitric oxide-related redox regulation. (source: tamariz-ellemann-2026-aging-is-associated-with-altered-estrogen-receptor-express.md)

Non-Hormonal Treatments

• Cognitive Behavioral Therapy (CBT) adapted for menopause (CBT-Meno) can lead to a 30% to 50% reduction in hot flash episodes by addressing the nervous system's stress response. (source: 2026-05-26.md)
• Dual neurokinin receptor antagonists like elinzanetant offer a non-hormonal option for reducing vasomotor symptoms by 74%. (source: 2026-05-26.md)
• The selective NK3R antagonist GS1-144 significantly reduces vasomotor symptoms frequency and severity in postmenopausal Chinese women, with 30 mg twice daily showing significant reductions at weeks 4 and 12, and 60 mg once daily at week 12. No liver safety risks were observed. (source: wang-2026-efficacy-and-safety-of-gs1-144-a-novel-neurokinin.md)
• Elinzanetant (brand name Lynkuet) was approved by the FDA in the second half of 2025 for the treatment of moderate to severe vasomotor symptoms associated with menopause. (source: treadway-2026-the-drug-update-recent-drug-approvals-summer-2026.md)

Sleep and Menopause

• Waking up at 2-3 AM after menopause is linked to hormonal changes affecting the brain and melatonin, as well as cortisol and nighttime anxiety. (source: 2026-04-27-gNHTRoOiB1I.md)
• Higher nighttime vasomotor symptoms frequency was indirectly associated with worse short-term emotional well-being through greater sleep disturbance, but only when vasomotor symptoms and sleep disturbance were measured subjectively. (source: wood-2026-examining-sleep-disturbance-as-a-mediator-of-the.md)
• Sleep disturbances, including fragmented sleep and clinical insomnia, are common in midlife women and may be partly attributed to the menopause transition. They often co-occur with depressive and anxiety symptoms, vasomotor symptoms, substance use, trauma history, and relationship stressors. Chronic sleep disturbance is related to poorer health and productivity. Evidence-based cognitive-behavioral sleep interventions are effective treatments. (source: jakubowski-2026-sleep-disturbances-in-midlife-women-prevalence-correlates-and.md)

Nutrition and Metabolism

• Hormonal changes during perimenopause and menopause impact metabolism, insulin sensitivity, and fat storage, requiring tailored nutritional strategies. (source: 2026-04-30-RQ0PFnzlM-U.md)
• GLP-1 medications are being explored for their potential benefits in managing weight and metabolic changes during menopause. (source: 2026-05-05-WCDcAfxpof8.md)
• Earlier menopause (≤45 years) is associated with lower lean body mass and higher risk of sarcopenia, particularly in women with higher BMI. (source: jeong-2026-association-of-age-at-menopause-with-lean-body.md)
• Metabolic dysfunction-associated steatotic liver disease (MASLD) severity and higher liver fat content are associated with lower lipoprotein(a) concentrations in postmenopausal females. (source: de-2026-sex-and-menopause-specific-inverse-associations-between-metabolic-dysfun.md)
• Estimated habitual dairy polar lipid intake was positively associated with post-intervention HDL-C concentrations in perimenopause women, though no significant associations were observed for total cholesterol, LDL-C, or triglycerides. (source: aleksejeva-2026-estimated-habitual-dairy-polar-lipid-exposure-and-post-intervent.md)
• The menopause transition is associated with significant increases in LDL-C and triglycerides, along with alterations in HDL-C composition and function, independent of chronological aging. (source: castaneda-2026-dyslipidemia-across-the-menopause-transition-mechanisms-trajector.md)

Diabetes and Menopause

• Type 2 diabetes mellitus (T2DM) is significantly associated with a greater number and severity of menopausal symptoms among Korean midlife women, particularly in the postmenopausal stage, after controlling for confounding variables. (source: yang-2026-association-between-type-2-diabetes-mellitus-and-menopausal.md)
• In a cross-sectional analysis of the BETTER registry, postmenopausal women with type 1 diabetes had higher risks of cardiovascular disease (RR 3.31), neuropathy (RR 2.22), retinopathy (RR 2.20), falls (RR 2.64), and moderate-to-severe depressive symptoms (RR 1.48) compared to premenopausal women with type 1 diabetes, despite similar HbA1c and insulin doses. (source: bonhoure-2026-physical-and-psychosocial-complications-faced-by-postmenopausal-wo.md)
• Endometriosis is associated with a 46% higher risk of type 2 diabetes (aHR 1.46; 95% CI 1.43, 1.50) compared with no endometriosis, with risk varying by subtype. The strongest associations were observed for 'other site' endometriosis (specified site: aHR 2.67; 95% CI 2.51, 2.84; unspecified site: aHR 2.47; 95% CI 2.35, 2.60). Associations were stronger among premenopausal women than postmenopausal women (aHR 1.55; 95% CI 1.50, 1.60) and those with BMI <30 kg/m² (aHR 2.39; 95% CI 2.34, 2.44). (source: fuzak-2026-endometriosis-subtypes-and-risk-of-type-2-diabetes.md)

Testosterone Therapy

• Transdermal testosterone significantly improved sexual desire and satisfaction in postmenopausal women with hypoactive sexual desire disorder, though compounded formulations showed variable hormone levels. (source: CeccattoAndrade2026-transdermal-testosterone-desire.md)
• Brazilian gynecologists widely prescribe testosterone therapy (TT) for hypoactive sexual desire disorder (95%) and other indications, with 93.9% prescribing compounded gels or creams, 54.9% implants, and 38% using gels for males. Most (78.1%) believe treatment should last up to 6 months, and 91.2% believe adverse effects sometimes occur. (source: valadares-2026-a-survey-of-brazilian-gynecologists-prescribing-practices-and.md)
• Of 1,213 Brazilian gynecologists surveyed, 85.6% aimed for TT to reach the reference range for premenopausal women, and 66% agreed or partially agreed to prescribe for breast cancer patients. (source: valadares-2026-a-survey-of-brazilian-gynecologists-prescribing-practices-and.md)
• The survey highlights a critical need for approved, standardized testosterone therapy options for women, as current practice relies heavily on compounded and unapproved formulations that risk supraphysiological levels. (source: valadares-2026-a-survey-of-brazilian-gynecologists-prescribing-practices-and.md)

Gut and Immune Health

• The menopause transition is associated with rising markers of compromised gut barrier integrity (FABP2, sCD14), suggesting a pathway for inflammation similar to animal models. (source: shieh-2026-markers-of-compromised-gut-epithelial-barrier-integrity-increase.md)
• Lifetime endogenous hormone exposure is associated with lower CD8+ T cell density in breast tumors, potentially influencing immune responses to cancer. (source: zhang-2026-association-between-cumulative-lifetime-exposure-to-reproductive-horm.md)
• Serum I-FABP levels are significantly higher in menopausal women compared to non-menopausal controls, suggesting compromised gut barrier integrity likely related to estrogen deficiency. Elevated I-FABP was associated with a 22.7-fold increased likelihood of menopause. (source: keskino-lu-2026-serum-intestinal-fatty-acid-binding-protein-as-a-biomarker.md)
• Co-supplementation of fructooligosaccharide (FOS) with soy isoflavone (SIF) in an estrogen-deprived rat model synergistically improved gut-brain axis function by modulating the gut microbiome, reducing oxidative stress and inflammation in the hippocampus and colon, and selectively activating ER-β expression without affecting serum estradiol or uterine weight. (source: chaudhary-2026-co-supplementation-of-fructooligosaccharide-with-soy-isoflavone-r.md)

Probiotics and Menopause

• A probiotic formula containing Levilactobacillus brevis KABP052, Lactiplantibacillus plantarum KABP051, and Pediococcus acidilactici KABP021 (1×10^9 CFU/day) was associated with improvements in menopause-associated symptoms and quality of life in perimenopausal and postmenopausal women, according to a randomized double-blind placebo-controlled trial. (source: rodr-guez-palmero-2026-efficacy-of-a-probiotic-formula-in-the-management.md)
• In an ovariectomized rat model of postmenopausal bone loss, a combination of the probiotic Lactobacillus casei (LC) and the microalga Chlorella vulgaris (CV) demonstrated significantly greater restoration of serum calcium and normalization of alkaline phosphatase (ALP) levels compared with monotherapies. The combination also produced the most pronounced increases in bone mineral density (BMD) and bone mineral content (BMC) at all skeletal sites, suggesting a promising multi-targeted natural strategy for postmenopausal osteoporosis. (source: gholami-2026-prospective-efficacy-of-a-novel-dual-pronged-strategy-combining.md)

Surgical Menopause

• Surgical menopause shows more pronounced early deterioration in left ventricular function (measured by LV GLS) compared to natural menopause, though differences may normalize by 6 months. (source: yaz-c-2026-early-subclinical-left-ventricular-dysfunction-after-surgical-menopau.md)
• Surgical menopause is associated with higher symptom severity and cumulative burden than natural menopause across multiple domains. (source: aggarwal-2026-multidimensional-menopausal-symptom-burden-in-singapore-marie.md)

Early Life Factors and Menopause

• Antenatal corticosteroid (ANS) exposure and LPS-induced chorioamnionitis induce acute molecular and structural changes in the developing fetal ovary, with potential implications for ovarian reserve and reproductive lifespan. (source: seah-2026-chorioamnionitis-and-glucocorticoids-elicit-acute-adverse-effects-on.md)

Neurological Conditions and Menopause

• Parkinson's disease differs between women and men in epidemiology, clinical manifestations, and treatment response, with sex hormones potentially modulating dopaminergic and neuroinflammatory circuits. The role of estradiol exposure and menopausal hormone therapy in disease progression warrants further study. (source: boone-2026-parkinson-s-disease-across-female-reproductive-stages-clinical-implic.md)
• Combined menopausal HRT (estrogen-progestin) was associated with an increased risk of Parkinson's disease (RR 1.40; 95% CI 1.07-1.82), while estrogen-only therapy showed no significant association (RR 1.01; 95% CI 0.81-1.27). (source: macedo-2026-differential-effects-of-hormone-therapy-formulations-on-parkinson-s.md)

Iron Metabolism and Menopause

• Macrophagic myofasciitis (MMF) may involve genetic susceptibility affecting iron regulation (TFR2, SLC40A1) and macrophage function, with potential implications for aluminum adjuvant persistence and menopausal iron dysregulation. (source: le-2026-macrophagic-myofasciitis-associated-with-transferrin-receptor-2-and.md)

Social Determinants of Health

• Lower education level, lower poverty income ratio (PIR), and renting a home were significantly associated with a shorter reproductive lifespan in women, affecting menopause timing. (source: li-2026-cumulative-social-determinants-of-health-and-reproductive-lifespan.md)
• Higher cumulative social disadvantage, including factors like food security and housing status, was associated with a shorter reproductive lifespan among women, with implications for menopause onset. (source: li-2026-cumulative-social-determinants-of-health-and-reproductive-lifespan.md)

Kidney Health

• Premature menopause (before age 40) was associated with a 50% higher odds of kidney stone disease (KSD) in two large cohorts, with HRT use partially attenuating but not eliminating the elevated risk. (source: usman-2026-premature-menopause-and-risk-of-kidney-stone-disease.md)
• Genetic predisposition further increased the hazard of KSD in women with premature menopause, with polygenic risk scores showing a dose-response relationship. (source: usman-2026-premature-menopause-and-risk-of-kidney-stone-disease.md)

Pelvic Health

• Vaginal bulge is the most common symptom of pelvic organ prolapse (POP), with stress urinary incontinence and pain being more bothersome in younger women (<50 years) compared to older women (≥70 years). (source: dunn-2026-perception-of-prolapse-associated-symptoms-by-age-a-cross-sectional.md)
• Dyspareunia in perimenopause and postmenopausal women is common and often undertreated, with genitourinary syndrome of menopause (GSM) being a frequent contributor. Management includes education, moisturizers, lubricants, and prescription therapy for GSM, usually low-dose vaginal estrogen. (source: broul-2026-assessment-and-management-of-dyspareunia-in-peri-and.md)
• Vaginitis is an incredibly common problem among women globally, with traditional therapies like antibiotics and antifungals effective but often requiring prolonged suppressive therapy due to recurrence. Newer therapies include partner treatment and adjunctive therapies like vaginal pH-modulating topicals. (source: mckinney-2026-evaluation-of-vaginitis-and-its-treatment.md)
• Menopause plays a key role in anal incontinence through hypoestrogenism-related changes in pelvic floor musculature, connective tissue integrity, and sphincter function, affecting approximately 2-21% of women with prevalence increasing after menopause. (source: ozcivit-2026-anal-incontinence-and-menopause.md)
• Radiofrequency therapy for genitourinary syndrome of menopause (GSM) shows significantly greater improvement in sexual function (FSFI score) compared to vaginal estrogen and placebo/moisturizer, but is comparable to laser therapy. Vaginal health outcomes are similar across all comparators, and adverse events are exclusively mild. (source: lumowa-2026-efficacy-and-safety-of-radiofrequency-as-a-treatment.md)
• In breast cancer survivors on aromatase inhibitors, vaginal estrogen provides greater improvement in vaginal dryness and dyspareunia than non-hormonal moisturizer, with minimal systemic estrogen exposure in most patients. (source: niravath-2026-vemora-vaginal-estrogen-versus-non-hormonal-moisturizer-in-women.md)
• Body image concerns are strongly negatively correlated with sexual self-efficacy and sexual function in postmenopausal women, suggesting that estrogen-related changes and psychological factors interact to affect sexual health. (source: aliaghdami-2026-body-image-concerns-and-their-association-with-sexual.md)
• Fractional carbon dioxide vaginal laser (fCO2) therapy for genitourinary syndrome of menopause (GSM) showed significant and durable improvement in urgency and overactive bladder symptoms out to 36 months, with 44.7% of women reporting being markedly or moderately better at 36 months on the PGI-I. (source: zwaans-2026-fractional-carbon-dioxide-vaginal-laser-for-the-treatment.md)
• Photobiomodulation (PBM) combined with pelvic floor muscle training (PFMT) significantly improved sexual function (FSFI total score) and showed clinically significant improvement in urinary function (ICIQ-SF) compared to PFMT+sham PBM in women with genitourinary syndrome of menopause. (source: oliveira-2026-photobiomodulation-and-pelvic-floor-training-for-genitourinary-syn.md)

Perimenopause Awareness

• 34% of US women aged 35+ reported uncertainty about their reproductive stage, peaking at 42% among those aged 40-44, with symptom confusion and attribution being the most common driver of uncertainty. (source: xu-2026-exploring-prevalence-and-drivers-of-perimenopause-uncertainty-among.md)
• Barriers to confirmation and care, including dismissive healthcare encounters, contributed to perimenopause uncertainty, particularly in women aged 40-44. (source: xu-2026-exploring-prevalence-and-drivers-of-perimenopause-uncertainty-among.md)

Digital Health Tools

• Menopause apps are experiencing a commercial boom, offering empowerment but also posing risks due to variable quality and potential misinformation. (source: glauser-2026-menopause-apps-offer-empowerment-but-pose-risks.md)

Epigenetics and Menopause

• Menopause leads to significant epigenetic transformations, including changes in DNA methylation, histone modifications, and microRNA expression, which can alter gene expression and increase susceptibility to chronic diseases like cardiovascular disease, osteoporosis, and hormone-related cancers. (source: zdemir-2026-menopause-and-epigenetic-changes-a-review.md)

Bone Health

• Biomass-derived humic acid (HA) mitigates metabolic dysfunction and bone loss from estrogen deficiency, supporting its potential as adjunct therapy. (source: andrade-2026-humic-acid-from-biomass-attenuates-ovariectomy-induced-metabolic-an.md)
• Women have higher incidence of hip fractures than men due to accelerated bone loss after menopause and higher incidence of falls. Other risk factors include low bone mineral density, prior fracture, and factors contributing to falls. (source: johannesdottir-2026-hip-fractures-a-review.md)
• In calcium-replete older women, calcium supplements had little effect on the response to antiresorptives, whereas low protein intake blunted their benefits. (source: papageorgiou-2026-dietary-and-supplemental-calcium-intake-and-bone-changes.md)
• Pregnancy- and lactation-associated osteoporosis (PLO) is a syndrome characterized by fragility fractures (most commonly vertebral, often multiple) occurring in late pregnancy or the early postpartum period. (source: hadji-2026-pregnancy-and-lactation-associated-osteoporosis-a-position-statement.md)
• A Transformer-LSTM hybrid model identified total type 1 collagen N-terminal propeptide (TP1NP) as the most critical physiological indicator affecting abnormal bone mineral density in perimenopausal women, with factors like educational level, body weight, and menopause before age 45 also exerting significant influence. The top 25 core features could explain 80% of the associated osteoporosis risk. (source: hu-2026-identification-and-importance-analysis-of-osteoporosis-risk-factors.md)
• Bone health literacy among breast cancer patients in perimenopause and early postmenopause is suboptimal; osteoporosis self-efficacy partially mediates the relationship between risk perception and bone health literacy, suggesting targets for intervention. (source: gai-2026-bone-health-literacy-and-risk-perception-in-perimenopausal.md)
• Management of chronic hypoparathyroidism and hyperparathyroidism in pregnancy and lactation requires intensive surveillance, with conventional therapy (activated vitamin D and calcium) continued throughout pregnancy but dosages may change unpredictably. For primary hyperparathyroidism, surgical treatment is recommended before conception, and parathyroidectomy in the second trimester for calcium above 2.85 mmol/L. (source: pilz-2026-management-of-chronic-hypoparathyroidism-and-hyperparathyroidism-in-pr.md)
• Strontium ranelate (SrR), used for postmenopausal osteoporosis, showed clastogenic and aneugenic effects in Allium cepa and toxic effects in Artemia salina assays, but co-treatment with resveratrol (RSV) reduced DNA damage, demonstrating antigenotoxic potential. (source: beir-o-2026-toxicological-and-cytogenetic-screening-of-strontium-ranelate-alone.md)
• L1 vertebral attenuation ≤160 HU on 100-kVp low-dose computed tomography (LDCT) identified postmenopausal women at three-fold higher fragility fracture risk, with performance comparable to the Fracture Risk Assessment Tool without BMD. In a healthy screenee cohort, L1 HU serves as the primary bone health signal, enabling early identification of at-risk individuals within existing LDCT workflows at no additional cost. (source: lin-2026-opportunistic-l1-attenuation-on-100-kvp-ldct-predicts-ten-year.md)
• CKD-associated osteoporosis in patients with CKD G4-5D requires a pragmatic treatment approach: optimize mineral metabolism including parathyroid hormone targeting before initiating bone-targeting drugs, and consider lifestyle modification. (source: evenepoel-2026-ckd-associated-osteoporosis-in-patients-with-ckd-g4-5d-a.md)
• Enhanced bioavailability vitamin D formulations (liposomal vitamin D3) significantly improved bone mineral density at femoral neck and lumbar spine, reduced bone turnover markers, and showed fewer fragility fractures compared to conventional cholecalciferol in postmenopausal women. (source: rasool-2026-vitamin-d-supplementation-and-bone-health-in-post-menopausal.md)
• Osteoporosis is a silent disease disproportionately affecting women during peri- and postmenopause due to oestrogen reduction causing resorption-formation uncoupling. Incidence is increasing. Screening to prevent fractures is essential, especially with prior fracture as the biggest risk factor. Diagnosis is by DXA T-score ≤ -2.5. X-rays can complement because a fragility fracture substantiates a diagnosis. (source: sztal-mazer-2026-menopause-and-osteoporosis-epidemiology-pathophysiology-screeni.md)
• Risk stratification for osteoporosis integrates fracture history, bone density, and FRAX risk. Non-pharmacological management includes adequate calcium intake and vitamin D sufficiency. HRT (MHT) should be considered in women aged <65 years with T-scores between -1.8 and -2.5. Pharmacotherapy is integral for fracture prevention; those at very high fracture risk may need referral for bone anabolic therapy. (source: goeltom-2026-menopause-and-osteoporosis-non-pharmacological-and-pharmacological.md)

Quality of Life

• Early postmenopause is a vulnerable period for impaired quality of life, with vasomotor and urogenital symptoms being important correlates of poorer well-being. (source: nasreen-2026-assessing-the-burden-of-menopausal-symptoms-and-their.md)
• In a cohort of 557 midlife Chinese women, earlier menopause and shorter reproductive life span were associated with higher adjusted sexual-domain scores on the Menopause-Specific Quality of Life (MENQOL) questionnaire, with significant differences for menopause before age 45 years (β = 0.83, 95% CI: 0.21, 1.44) and reproductive life span <30 years (β = 0.98, 95% CI: 0.21, 1.74). These sexual-domain associations were attenuated after adjustment for time since menopause, whereas associations with higher vasomotor symptoms (VMS) scores became apparent in postmenopausal analyses. (source: xie-2026-menarche-menopause-reproductive-life-span-and-menopause-specific-qualit.md)

Voice and Menopause

• Voice changes during menopause manifest as functional and work-related limitations, with the Menopausal Voice-Related Work Limitation Scale (MenoVWL-TR) being a valid and reliable tool for assessing these changes. (source: arslan-sar-mehmeto-lu-2026-menopausal-voice-related-work-limitation-scale-validi.md)

Treatment Preferences

• Women value safe and efficacious treatment for vasomotor symptoms, with high importance on avoiding long-term risks like blood clots and breast cancer. Reducing vasomotor symptoms frequency mattered over and above wider menopause symptoms, though treatment priorities were highly individual. (source: heidenreich-2026-women-s-treatment-preferences-for-moderate-to-severe-vasomotor.md)

Cardiovascular Health

• Heart failure and menopause commonly coexist in middle-aged women, but overlapping symptomatology often complicates diagnosis. Oestrogen exerts cardioprotective effects through anti-inflammatory and vasodilatory pathways and its decline has been proposed as a mechanistic explanation for myocardial fibrosis and diastolic dysfunction. (source: kwan-2026-overlap-between-heart-failure-and-menopause-diagnostic-challenges.md)
• Many women have suboptimal cardiovascular health (CVH), which declines during midlife. Few studies have characterized CVH across the menopausal transition or identified its sociodemographic and neighborhood determinants. (source: lin-2026-associations-of-sociodemographic-and-neighborhood-vulnerability-with-ca.md)
• Progesterone stimulates vasoactive factors, modulates lipid profiles, reduces inflammatory responses, inhibits platelet aggregation and cell proliferation, and lowers blood pressure, thereby contributing to the reduction of cardiovascular disease risk. (source: dos-2026-progesterone-and-vascular-function-mechanisms-and-therapeutic-implicati.md)
• Coronary microvascular dysfunction (CMD) is a central pathophysiological mechanism in heart failure with preserved ejection fraction (HFpEF), disproportionately affecting females, especially after menopause. Females exhibit distinct inflammatory and metabolic profiles, accelerated vascular and ventricular stiffening, and higher prevalence of CMD in the absence of obstructive coronary artery disease. (source: roy-2026-a-sex-specific-perspective-on-coronary-microvascular-dysfunction-in.md)
• Race differences in vascular health persist after adjusting for reproductive history in midlife women, according to a SWAN Study analysis. Non-Hispanic Black (NHB) women exhibit greater pulse pressure, estimated pulse wave velocity, and estimated vascular overload index compared with non-Hispanic White (NHW) women, and these differences are not explained by reproductive history or traditional risk factors. (source: tharpe-carter-2026-race-differences-in-vascular-health-persist-after-adjustment.md)
• Coexisting premature menopause (before age 40) and hypertension confer a markedly elevated risk of cardiovascular disease events (HR 1.64) compared with either factor alone, from a nationwide Korean cohort. (source: choi-2026-premature-menopause-and-hypertension-as-combined-risk-factors.md)
• A case report of a 72-year-old postmenopausal woman with ischemia and nonobstructive coronary arteries (INOCA) demonstrated that recurrent coronary vasospasm can lead to focal myocardial fibrosis and a hyperdynamic small left ventricle with supranormal ejection fraction, increasing risk of diastolic dysfunction and heart failure. (source: nguyen-2026-focal-myocardial-fibrosis-mimicking-hypertrophy-in-inoca-and.md)
• The menopause transition marks a period of accelerated cardiovascular risk, with ovarian ageing independently associated with adverse lipid profiles, fat redistribution, vascular dysfunction, and metabolic syndrome. Early, premature, surgical, and symptomatic menopause further amplify risk. Lifestyle optimization and lipid-lowering therapy remain powerful strategies. HRT is not recommended solely for primary or secondary CVD prevention, but may be offered for symptom management and bone protection in appropriately selected women, especially in cases of premature, early, or surgical menopause. (source: burns-2026-menopause-cardiovascular-health-and-the-role-of-hormone.md)
• In an ovariectomized rat model of estrogen deficiency, the SGLT2 inhibitor empagliflozin significantly improved endothelial function, enhanced eNOS activation, and restored nitric oxide levels, with effects comparable to estradiol. This suggests empagliflozin as a potential non-hormonal therapeutic strategy for endothelial dysfunction in postmenopausal conditions. (source: mad-2026-empagliflozin-improves-endothelial-function-in-an-ovariectomized-rat.md)

Aging and Super-Enhancers

• Super-enhancers play a pivotal role in aging and aging-related diseases by modulating key biological processes, including cell proliferation, differentiation, and senescence. Dysregulation of super-enhancers contributes to age-related disorders like atherosclerosis and type Ⅱ diabetes. (source: wang-2026-from-cell-to-disease-regulatory-networks-and-mechanisms.md)

Menstrual Cycle Disorders

• Sports physicians often lack systematic approaches to screening and managing menstrual cycle disorders in female athletes, with only 55.8% consistently assessing menstrual status and 34.1% evaluating menstrual regularity. Hormonal treatment is rarely prescribed, and many physicians express interest in standardized screening tools. (source: ducamp-2026-screening-and-management-of-menstrual-cycle-disorders-in.md)

Hypopituitarism

• Hypopituitarism is a rare but treatable complication of severe Russell's viper envenomation, with symptoms including secondary adrenal insufficiency, hypogonadotropic hypogonadism, and central hypothyroidism. Hormone replacement therapy can significantly improve clinical outcomes. (source: mohammed-2026-hypopituitarism-following-russell-s-viper-envenomation-in-banglade.md)

Endocrine Updates

• The 13th Annual EndoBridge Meeting highlighted contemporary approaches to managing acromegaly, subclinical thyroid dysfunction, osteoporosis, and hormonal treatment strategies for menopause and premature ovarian insufficiency. (source: yildiz-2026-endobridge-2025-pearls-and-highlights.md)

Sleep Apnea and Bladder Health

• Obstructive sleep apnea (OSAS) is associated with overactive bladder (OAB) through mechanisms like intermittent hypoxia and autonomic nervous system dysregulation. Female-specific factors such as menopause and estrogen deficiency may amplify bladder symptoms. (source: batur-2026-obstructive-sleep-apnea-syndrome-and-overactive-bladder-expanding.md)

Bone Health Awareness

• Women aged 40-65 with limited income in Shanghai have limited bone-health knowledge and preventive practices, despite considering bone health important. Higher educational attainment and regular physical activity are associated with slightly higher knowledge scores. (source: zhou-2026-what-are-the-attitudes-awareness-levels-and-practices.md)

Endometriosis and Menopause

• Most postmenopausal women with endometriosis are asymptomatic (55.7%), but a small subset may have ectopic implants that remain biologically active and progress to malignant precursor forms. Pelvic or abdominal pain is the most common symptom among symptomatic women. (source: fitas-2026-menopause-and-endometriosis-symptoms-and-risk-of.md)
• Postmenopausal endometriosis appears to confer an increased risk of ovarian carcinoma, particularly ovarian clear cell carcinoma (OCCC) and ovarian endometrioid carcinoma (OEC). (source: fitas-2026-menopause-and-endometriosis-symptoms-and-risk-of.md)

Testosterone-to-Estradiol Ratio

• In postmenopausal women with HFpEF, a lower testosterone-to-estradiol ratio (T/E2) is associated with greater systemic inflammation, worse diastolic hemodynamics, and higher odds of short-term clinical events, suggesting T/E2 may serve as a candidate endocrine-inflammatory marker for HFpEF phenotyping. (source: qi-2026-association-of-testosterone-to-estradiol-ratio-with-inflammation-and-cli.md)

Reproductive Lifespan in Cancer Survivors

• Anti-Müllerian hormone (AMH) levels decline significantly after cancer treatment but improve between 6 and 12-24 months post-treatment. Long-term AMH trajectories in cancer survivors align with age-matched healthy controls, indicating similar reproductive aging patterns. (source: balachandren-2026-assessing-the-reproductive-lifespan-of-female-cancer-survivors.md)

Premature Ovarian Insufficiency

• Premature menopause (POI) confronts women with menopause before age 40, creating temporal dislocation where bodies age 'out of sync' with chronological age and social environment, leading to internalized ageism. (source: budke-2026-out-of-time-out-of-place-temporal-desynchronization.md)
• Healthcare encounters for POI are frequently marked by misrecognition and epistemic injustice as it falls outside age-normative clinical expectations. (source: budke-2026-out-of-time-out-of-place-temporal-desynchronization.md)

Cancer Survivors and Menopause

• Menopausal symptoms are common after cancer treatment, with wide-ranging impacts on cancer survivors' daily living. Cancer survivors have unmet needs in treatment, support, and information for managing menopausal symptoms. Between 26 and 80% were untreated or self-managing their symptoms, 15-76% found their treatments ineffective, and 23-68% desired additional treatment. (source: serwaa-2026-a-mixed-studies-systematic-review-of-the-unmet.md)
• Among endometrial cancer survivors aged 18-51, short-term use of vaginal estrogen therapy was not associated with an increased risk of cancer recurrence (HR 0.87; 95% CI 0.60-1.27), suggesting it may be a safe option for managing genitourinary symptoms. (source: hsu-2026-vaginal-estrogen-therapy-utilization-and-associated-outcomes-in.md)

Cancer and Cardiovascular Disease

• Mortality from both gynecologic cancer and cardiovascular disease (CVD) in US women aged ≥25 years showed a 49.0% increase in total deaths from 1999 to 2023, though the overall age-adjusted mortality rate remained stable. Mortality was highest among women aged ≥85 years, with a marked rise after 2018. Non-Hispanic Black women and non-metropolitan residents consistently had the highest mortality. (source: liu-2026-mortality-trends-in-us-patients-with-gynecologic-cancer.md)

Cervical Cancer Screening

• An interpretable machine learning (ML) tool for cervical cancer screening achieved a clinical sensitivity of 92.5% for detecting high-grade squamous intraepithelial lesions or worse (HSIL+), significantly outperforming manual methods (84.2%). Menopausal tissue atrophy or active vaginal infections caused no significant performance degradation. The ML system compressed median slide-review time by 63.0% and increased daily screening capacity by 175%. (source: chang-2026-an-explainable-machine-learning-approach-for-cervical-cancer.md)

Endometrial Cancer Screening

• Black women have significantly lower completion rates for transvaginal ultrasound for endometrial cancer screening compared with White women (75.7% vs 88.9%), primarily due to fibroids impairing endometrial visibility; however, when completed, the test retains excellent accuracy for excluding cancer. (source: rotenberg-2026-racial-differences-in-sonographic-evaluation-in-suspected-cases.md)

Chronic Low Back Pain

• The Integrated Resilience Method, a six-pillar framework for women 50+ with chronic low back pain (CLBP), addresses biopsychosocial factors including hormonal change, sarcopenia, sleep disruption, fear-avoidance, and caregiving stress. The framework prioritizes exercise, pain education, and self-efficacy as the strongest evidence-based components, with nutrition and stress-resilience practices as adjunct supports. (source: padernal-2026-the-integrated-resilience-method-a-whole-person-framework-for.md)

Hypothyroidism and Relaxation

• Progressive muscle relaxation (PMR) significantly reduced fatigue and depressive symptoms in patients with hypothyroidism despite standard thyroid hormone replacement therapy, with large effect sizes in a randomized controlled trial. (source: safarabadi-2026-the-effect-of-progressive-muscle-relaxation-technique-on.md)

Menopause in the Workplace

• Menopause is an increasingly recognized workplace health issue with significant implications for nursing practice, workforce retention, and employee wellbeing. Symptoms can impact performance, confidence, and attendance, but menopause remains under-discussed due to stigma and limited organizational support. Promoting awareness and normalizing conversations around menopause are essential to improving staff experience and sustaining a resilient workforce. (source: peate-2026-menopause-in-the-workplace.md)

Military and Menopause

• A scoping review identified 18 articles on perimenopause and menopause in military contexts, mostly US-based (83%) and among veterans (67%). Key themes include menopausal knowledge, HRT use, experience of menopause, and available resources. Significant knowledge gaps remain, particularly regarding geographic differences and policy development. (source: segovia-2026-perimenopause-and-menopause-in-the-military-a-scoping.md)

Eye Health and Aging

• The Nrf2 signaling pathway plays a key role in protecting against oxidative stress and inflammation in age-related eye diseases (AREDs) like diabetic retinopathy, cataract, glaucoma, and age-related macular degeneration. Nrf2 activators, including noncoding RNAs and external substances, show promise in preclinical models, but issues like ocular delivery, long-term safety, and risks of chronic Nrf2 activation remain before clinical translation. (source: xinyu-2026-targeting-of-nuclear-factor-erythroid-2-related-factor-2.md)

Breast Cancer and Tissue Stiffness

• High mammographic breast density is a strong independent risk factor for sporadic breast cancer. In a study of 108 postmenopausal women, dense breast tissue exhibited a distinct extracellular proteomic signature enriched for proteins associated with platelet activation. Several platelet-associated proteins were also elevated in ER+ breast cancers. Low-dose acetylsalicylic acid (ASA) did not modulate these proteins, suggesting that stiffness-induced platelet activation may occur via mechanotransduction rather than biochemical pathways. In a 3D in vitro model, increased matrix stiffness representative of dense breasts promoted a procoagulant platelet phenotype. These findings highlight platelet mechanobiology as a potential target for breast cancer prevention and therapy. (source: heenkenda-2026-tissue-stiffness-driven-platelet-activation-emerges-as-a-potentia.md)

New Research Findings

• Neddylation of NFATc1 and Runx2 regulates osteoclast-osteoblast balance and represents a dual-action therapeutic target for postmenopausal osteoporosis. (source: lee-2026-neddylation-of-nfatc1-and-runx2-regulates-osteoclast-osteoblast-balance.md)
• There is no significant association between low bone mineral density and hearing loss in premenopausal females. (source: howe-2026-hearing-loss-and-low-bone-mineral-density-in.md)
• RARRES2 deficiency inhibits postmenopausal osteoporosis by promoting ferroptosis-mediated osteoclast differentiation via Nrf2/GPX4 axis inhibition. (source: wang-2026-rarres2-deficiency-inhibits-postmenopausal-osteoporosis-by-promoting-f.md)
• The 'silver economy' of women's health: entrepreneurship and service models in China's menopause health sector. (source: zhang-2026-the-silver-economy-of-women-s-health-entrepreneurship-and.md)
• Association between endogenous sex hormones and cardiovascular-kidney-metabolic in US adults: a population-based study. (source: xie-2026-association-between-endogenous-sex-hormones-and-cardiovascular-kidney-m.md)
• The tumour microenvironment (TME) composition modulates tamoxifen benefit in postmenopausal ER+HER2- breast cancer. Low immune, intermediate endothelial, and low/intermediate fibroblast abundances are associated with improved benefit from tamoxifen, suggesting that both immune and stromal compartments influence endocrine treatment efficacy. (source: camargo-romera-2026-the-tumour-microenvironment-influences-long-term-tamoxifen-b.md)

Ideas

• Investigate the relationship between Nrf2 signaling pathway and age-related eye diseases in postmenopausal women.
• Explore the potential of RARRES2 deficiency as a therapeutic target for postmenopausal osteoporosis.
• Develop a comprehensive framework for addressing menopause in the workplace, including awareness, support, and policy development.
• Examine the impact of testosterone-to-estradiol ratio on cardiovascular health in postmenopausal women.
• Investigate the role of probiotic supplementation in modulating gut barrier integrity and inflammation during menopause.
• Examine the interaction between type 2 diabetes and menopausal symptom burden in diverse populations.
• Explore the combined effect of premature menopause and hypertension on cardiovascular risk in different racial/ethnic groups.
• Evaluate the clinical utility of inflammatory biomarkers like GlycA and complement factors for cognitive risk stratification in midlife women.
• Determine the impact of fibroids on endometrial cancer screening accuracy in Black women and develop alternative screening strategies.
• Investigate the role of mTORC1 signaling in the medial prefrontal cortex as a target for rapid-acting antidepressants in menopause-associated depression.
• Explore the therapeutic potential of combined estrogen receptor modulation and Fas pathway inhibition for neuroprotection in age-related neurodegenerative disorders.
• Examine the relationship between endometriosis subtypes and type 2 diabetes risk, considering effect modification by menopausal status and BMI.
• Evaluate the clinical utility of opportunistic L1 attenuation measurement on LDCT for fracture risk prediction in postmenopausal women.
• Investigate how tumour microenvironment composition can guide endocrine therapy decisions in postmenopausal breast cancer.
• Explore the translational potential of FOS and soy isoflavone co-supplementation for restoring gut-brain axis function in postmenopausal women.
• Assess the impact of liposomal vitamin D3 formulations on fracture risk and bone density in larger, longer-term trials.
• Investigate the role of platelet mechanobiology as a target for breast cancer prevention in women with dense breast tissue.
• Explore the potential of the Lactobacillus casei and Chlorella vulgaris combination as a natural strategy for postmenopausal osteoporosis in clinical trials.
• Examine the relationship between HRT timing and duration and LATE-NC risk in diverse cohorts to confirm neuroprotective effects.